Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H44O3 |
| Molecular Weight | 428.6472 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
InChI
InChIKey=JKWKMORAXJQQSR-MOPIKTETSA-N
InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1
| Molecular Formula | C28H44O3 |
| Molecular Weight | 428.6472 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Curator's Comment: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a semisynthetic anabolic-androgenic steroid derived from testosterone. Nandrolone is used in the form of a variety of long-acting prodrug esters for intramuscular injection, the most common of which are nandrolone decanoate. Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testis. Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. Synthetic version of nandrolone was developed in 1950. But nandrolone for sale appeared later only in 1962 in the form of decanoate under the trade name Deca-Durabolin (Organon company).
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL1871 |
|||
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NANDROLONE DECANOATE Approved UseNandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. Launch Date2010 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
36.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
219.9 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Metabolic effects of nandrolone decanoate and resistance training in men with HIV. | 2002-12 |
|
| Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective. | 2002-11-15 |
|
| Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. | 2002-10-25 |
|
| Synthesis of nitrile derivatives of estrogens. | 2002-10-21 |
|
| Urine nandrolone metabolites: false positive doping test? | 2002-10 |
|
| Repeated anabolic-androgenic steroid treatment during adolescence increases vasopressin V(1A) receptor binding in Syrian hamsters: correlation with offensive aggression. | 2002-09 |
|
| Successful DNA typing of a urine sample in a doping control case using human mitochondrial DNA analysis. | 2002-09 |
|
| Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. | 2002-09 |
|
| Nandrolone excretion is not increased by exhaustive exercise in trained athletes. | 2002-09 |
|
| Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. | 2002-08-30 |
|
| The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. | 2002-08-20 |
|
| Nandrolone: generic now in stock. | 2002-08-09 |
|
| Treatment of menstruation-associated recurrence of hereditary pancreatitis with pharmacologic ovarian suppression. | 2002-08-01 |
|
| In situ detection and quantification of bursa of fabricius cellular proliferation or apoptosis in normal or steroid-treated neonatal chicks. | 2002-08 |
|
| Molecular imprinted polymer coated QCM for the detection of nandrolone. | 2002-08 |
|
| Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. | 2002-08 |
|
| The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. | 2002-07 |
|
| Nandrolone decanoate treatment induces changes in contractile responses of rat untrained fast-twitch skeletal muscle. | 2002-07 |
|
| Steroid receptor concentration in aged rat hindlimb muscle: effect of anabolic steroid administration. | 2002-07 |
|
| Nandrolone (Deca Durabolin) disappears in U.S., generic may return in July. | 2002-06-28 |
|
| Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. | 2002-06-15 |
|
| Treatment for HIV wasting withdrawn. | 2002-06 |
|
| Anti-androgenic and hair growth promoting activities of Lygodii spora (spore of Lygodium japonicum) I. Active constituents inhibiting testosterone 5alpha-reductase. | 2002-05 |
|
| Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. | 2002-05 |
|
| The popliteal-artery entrapment syndrome in a patient using anabolic steroids. | 2002-04-18 |
|
| Effects of withdrawal from anabolic androgenic steroids on aggression in adult male rats. | 2002-04-01 |
|
| Role of androgens in female genital sexual arousal: receptor expression, structure, and function. | 2002-04 |
|
| Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. | 2002-04 |
|
| Randomized prospective comparison between erythropoietin and androgens in CAPD patients. | 2002-04 |
|
| Aromatase and breast cancer: W39R, an inactive protein. | 2002-04 |
|
| Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of methyltestosterone (17 alpha-methylandrost-4-en-17 beta-ol-3-one) and nandrolone (estr-4-en-17 beta-ol-3-one) metabolites. | 2002-03-22 |
|
| The human ovarian surface epithelium is an androgen responsive tissue. | 2002-03-18 |
|
| Endogenous nandrolone metabolites in human urine. Two-year monitoring of male professional soccer players. | 2002-03-13 |
|
| Effect of dienogest-containing oral contraceptives on lipid metabolism. | 2002-03 |
|
| Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. | 2002-03 |
|
| The anabolic androgenic steroid, nandrolone decanoate, increases the density of Fos-like immunoreactive neurons in limbic regions of guinea-pig brain. | 2002-02 |
|
| Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids. | 2002-02 |
|
| Abuse of performance-enhancing drugs in sport. | 2002-02 |
|
| Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. | 2002-02 |
|
| Human nutritional supplements in the horse: comparative effects of 19-norandrostenedione and 19-norandrostenediol on the 19-norsteroid profile and consequences for doping control. | 2002-01-25 |
|
| Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. | 2002-01-11 |
|
| Hair analysis of seven bodybuilders for anabolic steroids, ephedrine, and clenbuterol. | 2002-01 |
|
| Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. | 2002-01 |
|
| Inhibition of oestrone sulphatase activity by tibolone and its metabolites. | 2002-01 |
|
| Effect of combined treatment with nandrolone and cocaine on the NMDA receptor gene expression in the rat nucleus accumbens and periaqueductal gray. | 2002 |
|
| Estradiol valerate/dienogest. | 2002 |
|
| Advances in male hormonal contraception. | 2001-12 |
|
| Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. | 2001-12 |
|
| [Urinary nandrolone metabolites in antidoping control]. | 2001-09 |
|
| Sport nutritional supplements: quality and doping controls. | 2001 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:27 GMT 2025
by
admin
on
Mon Mar 31 18:23:27 GMT 2025
|
| Record UNII |
H45187T098
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
||
|
FDA ORPHAN DRUG |
569116
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C003297
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
DTXSID7023352
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
206-639-3
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
H45187T098
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
9677
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
360-70-3
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
DB08804
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
m7720
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
31494
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL1200946
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
SUB03384MIG
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
C1172
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
H45187T098
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
100000090393
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
1455000
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
Nandrolone decanoate
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY | |||
|
1881
Created by
admin on Mon Mar 31 18:23:27 GMT 2025 , Edited by admin on Mon Mar 31 18:23:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |